294190-17-3

Basic information

• Product Name: 5-CHLORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER
• Synonyms: 5-CHLORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER;Methyl 5-chloro-2-Methyl-3-nitrobenzoate;Benzoic acid, 5-chloro-2-Methyl-3-nitro-, Methyl ester
• CAS NO: 294190-17-3
• Molecular Formula: C₉H₈ClNO₄
• Molecular Weight: 229.618
• Mol File: 294190-17-3.mol

Chemical Properties

• Boiling Point: 317.1±37.0 °C(Predicted)
• Appearance: /
• Density: 1.371±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 5-CHLORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER(294190-17-3)
• EPA Substance Registry System: 5-CHLORO-2-METHYL-3-NITRO-BENZOIC ACID METHYL ESTER(294190-17-3)

Safety Data

• Hazardous Substances Data: 294190-17-3(Hazardous Substances Data)

Usage

Uses

Used in Laboratory Research:
5-Chloro-2-methyl-3-nitro-benzoic acid methyl ester is utilized as a reagent in the synthesis of various organic compounds, contributing to the advancement of chemical research and the development of new materials.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, 5-Chloro-2-methyl-3-nitro-benzoic acid methyl ester is employed as a key intermediate in the production of a range of drugs. Its chemical properties make it suitable for the creation of medicinal compounds, potentially leading to the discovery of new therapeutic agents.
Used in Organic Synthesis:
5-Chloro-2-methyl-3-nitro-benzoic acid methyl ester is also applied in organic synthesis processes, where its unique structure and reactivity facilitate the formation of complex organic molecules, which are essential in various chemical and industrial applications.
Used in Industrial Applications:
Beyond the laboratory and pharmaceutical settings, 5-Chloro-2-methyl-3-nitro-benzoic acid methyl ester finds use in other industrial applications, capitalizing on its chemical versatility to contribute to the production of a diverse array of products.

Upstream product

• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 154257-81-5 5-chloro-2-methyl-3-nitrobenzoic acid 
• 74-88-4 methyl iodide 
• 7499-06-1 5-chloro-2-methylbenzoic acid 
• 67-56-1 methanol 

Relevant articles and documents

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat

Posttranslational methylation of histones plays a critical role in gene regulation. Misregulation of histone methylation can lead to oncogenic transformation. Enhancer of Zeste homologue 2 (EZH2) methylates histone 3 at lysine 27 (H3K27) and abnormal methylation of this site is found in many cancers. Tazemetostat, an EHZ2 inhibitor in clinical development, has shown activity in both preclinical models of cancer as well as in patients with lymphoma or INI1-deficient solid tumors. Herein we report the structure-activity relationships from identification of an initial hit in a high-throughput screen through selection of tazemetostat for clinical development. The importance of several methyl groups to the potency of the inhibitors is highlighted as well as the importance of balancing pharmacokinetic properties with potency.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

SUBSTITUTED BENZENE COMPOUNDS

The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.